Loading clinical trials...
Loading clinical trials...
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME)
Conditions
Interventions
Durvalumab
Oleclumab
Locations
1
Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Start Date
January 1, 2021
Primary Completion Date
January 1, 2023
Completion Date
January 1, 2023
Last Updated
November 17, 2020
NCT06305754
NCT07190248
NCT07100080
NCT04657068
NCT07195695
NCT06357533
Lead Sponsor
University Health Network, Toronto
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions